New Delhi, June 15: Novavax Inc, which has a vaccine manufacturing agreement with Serum Institute of India, said its COVID-19 vaccine candidate was highly effective with 90.4 per cent efficacy overall and also showed high efficacy against predominantly circulating variants.
It said that the vaccine candidate 'NVX-CoV2373' demonstrated 100 per cent protection against moderate and severe disease, 90.4 per cent efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.
|